FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2890178630> ?p ?o ?g. }

• W2890178630 endingPage "4030" @default.
• W2890178630 startingPage "4030" @default.
• W2890178630 abstract "4030 Background: T + chemo is standard 1st line therapy (tx) for HER2+ GEA patients (pts). However, pts typically progress within 6-8 months, with up to 30% demonstrating loss of HER2 positivity. No HER2 targeted agents have been shown effective in the post-T setting. We report the results of M, a novel anti-HER2 monoclonal antibody + P (anti-PD-1) in HER2+ GEA pts in 2nd line post T progression and describe a biomarker enrichment strategy that compensates for tumor heterogeneity. Methods: HER2+ (pre-T testing) PD-L1-unselected GEA pts were enrolled. Endpoints include safety, objective response rate (ORR) by RECIST, and progression free survival (PFS). Exploratory endpoints include ERBB2 amplification (amp) status pre-M+P tx circulating-tumor DNA (ctDNA) by NGS (Guardant360) and PD-L1 on archival tissue by IHC (22C3 pharmDx). Results: As of 1/10/18, 60 pts were dosed in cohort expansion; 30 in North America (NA), 30 in Asia (A). Tx was well tolerated, with 13% of pts having TRAE ≥ grade 3, 3 drug-related SAEs, and 2 cases of autoimmune hepatitis and 1 pneumonitis. ERBB2 amp was detected by ctDNA in 61% of pts tested, mainly distal gastric cancer (GC) over proximal GEJ pts, and was inversely correlated with acquired driver mutations. PD-L1 was positive in 34% of pts tested, and was independent of clinical metrics but was enriched in ctDNA ERRB2+ pts (41% vs. 33%). Of 57 evaluable pts to date in expansion (30 NA and 27 A), best ORR was 16% and disease control rate (DCR) was 54%. Both ctDNA ERBB2 amp and PD-L1 positivity predicted response (24% vs. 0% [p = .0655] and 36% vs. 5% [p = .0367], respectively). In ctDNA ERBB2+/PD-L1+ pts, which were all GC, the ORR was 57% and DCR 86%. Conclusions: M+P is a well-tolerated regimen with antitumor activity in 2nd line HER2+ GEA. Consistent with prior tissue-based reports, many GEA pts progressing on T have lost ERBB2amp. ERBB2 status by ctDNA NGS post-T could predict response to M+P, particularly in PD-L1+ pts. Our results suggest that M+P has encouraging preliminary activity in patients with advanced GC, and that biomarker selection based on ctDNA ERBB2 and PD-L1 could enrich for the responding population. Clinical trial information: NCT02689284." @default.
• W2890178630 created "2018-09-27" @default.
• W2890178630 creator A5000347168 @default.
• W2890178630 creator A5005194853 @default.
• W2890178630 creator A5005925636 @default.
• W2890178630 creator A5012481334 @default.
• W2890178630 creator A5022731264 @default.
• W2890178630 creator A5025615584 @default.
• W2890178630 creator A5034428260 @default.
• W2890178630 creator A5042756782 @default.
• W2890178630 creator A5050684671 @default.
• W2890178630 creator A5052643581 @default.
• W2890178630 creator A5056408400 @default.
• W2890178630 creator A5057146015 @default.
• W2890178630 creator A5057554500 @default.
• W2890178630 creator A5059886787 @default.
• W2890178630 creator A5062154678 @default.
• W2890178630 creator A5069669113 @default.
• W2890178630 creator A5071994294 @default.
• W2890178630 creator A5084809433 @default.
• W2890178630 creator A5087342677 @default.
• W2890178630 creator A5090604653 @default.
• W2890178630 date "2018-05-20" @default.
• W2890178630 modified "2023-10-17" @default.
• W2890178630 title "Margetuximab (M) plus pembrolizumab (P) in ERBB2-amplified PD-L1+ gastroesophageal adenocarcinoma (GEA) post trastuzumab (T)." @default.
• W2890178630 doi "https://doi.org/10.1200/jco.2018.36.15_suppl.4030" @default.
• W2890178630 hasPublicationYear "2018" @default.
• W2890178630 type Work @default.
• W2890178630 sameAs 2890178630 @default.
• W2890178630 citedByCount "5" @default.
• W2890178630 countsByYear W28901786302019 @default.
• W2890178630 countsByYear W28901786302020 @default.
• W2890178630 countsByYear W28901786302022 @default.
• W2890178630 crossrefType "journal-article" @default.
• W2890178630 hasAuthorship W2890178630A5000347168 @default.
• W2890178630 hasAuthorship W2890178630A5005194853 @default.
• W2890178630 hasAuthorship W2890178630A5005925636 @default.
• W2890178630 hasAuthorship W2890178630A5012481334 @default.
• W2890178630 hasAuthorship W2890178630A5022731264 @default.
• W2890178630 hasAuthorship W2890178630A5025615584 @default.
• W2890178630 hasAuthorship W2890178630A5034428260 @default.
• W2890178630 hasAuthorship W2890178630A5042756782 @default.
• W2890178630 hasAuthorship W2890178630A5050684671 @default.
• W2890178630 hasAuthorship W2890178630A5052643581 @default.
• W2890178630 hasAuthorship W2890178630A5056408400 @default.
• W2890178630 hasAuthorship W2890178630A5057146015 @default.
• W2890178630 hasAuthorship W2890178630A5057554500 @default.
• W2890178630 hasAuthorship W2890178630A5059886787 @default.
• W2890178630 hasAuthorship W2890178630A5062154678 @default.
• W2890178630 hasAuthorship W2890178630A5069669113 @default.
• W2890178630 hasAuthorship W2890178630A5071994294 @default.
• W2890178630 hasAuthorship W2890178630A5084809433 @default.
• W2890178630 hasAuthorship W2890178630A5087342677 @default.
• W2890178630 hasAuthorship W2890178630A5090604653 @default.
• W2890178630 hasConcept C121608353 @default.
• W2890178630 hasConcept C126322002 @default.
• W2890178630 hasConcept C143998085 @default.
• W2890178630 hasConcept C2776694085 @default.
• W2890178630 hasConcept C2777701055 @default.
• W2890178630 hasConcept C2777714996 @default.
• W2890178630 hasConcept C2778822529 @default.
• W2890178630 hasConcept C2779524853 @default.
• W2890178630 hasConcept C2779786085 @default.
• W2890178630 hasConcept C2779984678 @default.
• W2890178630 hasConcept C2780057760 @default.
• W2890178630 hasConcept C530470458 @default.
• W2890178630 hasConcept C71924100 @default.
• W2890178630 hasConcept C72563966 @default.
• W2890178630 hasConcept C90924648 @default.
• W2890178630 hasConceptScore W2890178630C121608353 @default.
• W2890178630 hasConceptScore W2890178630C126322002 @default.
• W2890178630 hasConceptScore W2890178630C143998085 @default.
• W2890178630 hasConceptScore W2890178630C2776694085 @default.
• W2890178630 hasConceptScore W2890178630C2777701055 @default.
• W2890178630 hasConceptScore W2890178630C2777714996 @default.
• W2890178630 hasConceptScore W2890178630C2778822529 @default.
• W2890178630 hasConceptScore W2890178630C2779524853 @default.
• W2890178630 hasConceptScore W2890178630C2779786085 @default.
• W2890178630 hasConceptScore W2890178630C2779984678 @default.
• W2890178630 hasConceptScore W2890178630C2780057760 @default.
• W2890178630 hasConceptScore W2890178630C530470458 @default.
• W2890178630 hasConceptScore W2890178630C71924100 @default.
• W2890178630 hasConceptScore W2890178630C72563966 @default.
• W2890178630 hasConceptScore W2890178630C90924648 @default.
• W2890178630 hasIssue "15_suppl" @default.
• W2890178630 hasLocation W28901786301 @default.
• W2890178630 hasOpenAccess W2890178630 @default.
• W2890178630 hasPrimaryLocation W28901786301 @default.
• W2890178630 hasRelatedWork W1584669207 @default.
• W2890178630 hasRelatedWork W2024340610 @default.
• W2890178630 hasRelatedWork W2611760803 @default.
• W2890178630 hasRelatedWork W2899528185 @default.
• W2890178630 hasRelatedWork W3031735911 @default.
• W2890178630 hasRelatedWork W3044257003 @default.
• W2890178630 hasRelatedWork W3137273825 @default.
• W2890178630 hasRelatedWork W3177161119 @default.
• W2890178630 hasRelatedWork W3194663175 @default.
• W2890178630 hasRelatedWork W4313546036 @default.

• next